N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.

Benzer Materyaller

• Protection from Doxorubicin-Induced Cardiomyopathy Using the Modified Anthracycline N-Benzyladriamycin-14-valerate (AD 198)
  Yazar:: Cai, Chun, ve diğerleri
  Baskı/Yayın Bilgisi: (2010)
• Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype.
  Yazar:: Kamath, N., ve diğerleri
  Baskı/Yayın Bilgisi: (1993)
• Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.
  Yazar:: Ganapathi, R., ve diğerleri
  Baskı/Yayın Bilgisi: (1988)
• Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model
  Yazar:: Christowitz, Claudia, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma
  Yazar:: Edwards, Shanique K E, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)